Global Access Dx (GADx) published an article by Dr Alison Wakeham exploring how modern lateral flow technology can help make allergen-specific IgE testing faster, more affordable, and potentially suitable for at-home use.

Global Access Diagnostics (GADx) is a leading developer and manufacturer of advanced lateral flow and rapid diagnostic technologies. Leveraging our core technology platforms, we work with governments and international organisations, reinvesting our profits to deliver high quality and affordable diagnostics for everyone. As a CRO, GADx offers world-leading expertise for contract research and development as well as helping companies to scale-up manufacturing (prototyping to pilot-scale) and then facilitate local manufacturing and/or onward distribution throughout the world, with a focus on low- and middle-income countries. We are actively seeking partners for commercialisation of our product pipeline and those looking to create, scale or manufacture a new point-of-need diagnostic. GADx is a Global Access Health (GAH) company and combines expertise in rapid diagnostics development from Mologic Ltd with low-cost manufacturing. We are headquartered in Bedford in the United Kingdom and have a US subsidiary, Mologic Inc. situated in Maine, New Gloucester. For more information: www.globalaccessdx.com

Founded 2003